Table 1.
Patient characteristics for the 29 patients where pre-therapy biopsies were analysed for microRNA expression.
| Sex | |
| Male | 9 |
| Female | 20 |
| Age | |
| Years | 63.0 (range 28.0–87.0) |
| Location | |
| Anal canal | 19 |
| Anal margin | 10 |
| Size | |
| Median (cm) | 5.5 (range 1.9–12.0) |
| T-stage | |
| T1 | 1 |
| T2 | 13 |
| T3 | 8 |
| T4 | 7 |
| N-stage (TNM 4) | |
| N0 | 14 |
| N1 | 6 |
| N2 | 5 |
| N3 | 4 |
| Stage (TNM 7) | |
| I | 1 |
| II | 11 |
| III A | 7 |
| III B | 10 |
| IV | 0 |
| Treatment | |
| RT and FuMi | 17 (*2 also surgery) |
| RT and CiFu | 10 |
| RT alone | 1 |
| Surgery alone | 1 |
| High-Risk HPV | |
| Positive | 23 |
| Negative | 6 |
TNM classification according to 4th edition, stage according to 7th edition. Chemotherapy was administered according to the standard combination of fluorouracil and Mitomycin C (FuMi) and cisplatin and fluorouracil (CiFu).